Wednesday, August 19th 2026 - 21:47 UTC
Despite the vaccine label used in much of the coverage, this is not a preventive measure but a treatment
Pharmaceutical companies Merck, known as MSD outside the United States and Canada, and Moderna announced on Wednesday that their individualized neoantigen therapy, intismeran autogene, met its endpoints in a phase 3 trial in melanoma patients. It is the first positive result at that stage for an mRNA-based cancer treatment.
The INTerpath-001 study enrolled 1,137 patients with completely resected stage IIB to IV melanoma and no prior systemic treatment. Participants were assigned in a two-to-one ratio: one group received intismeran combined with pembrolizumab, the immunotherapy Merck markets as Keytruda, and the other pembrolizumab alone, the standard of care in that setting. The trial met its primary endpoint of recurrence-free survival and its secondary endpoint of distant metastasis-free survival.
Despite the vaccine label used in much of the coverage, this is not a preventive measure but a treatment. Each patient's resected tumour is analysed to identify the mutations specific to that cancer, and that information is used to design a tailored mRNA therapy intended to train the immune system to recognise and attack malignant cells should they return.
